Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Summary
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Astellas Pharma : Receives “2021 Award for Excellence in Corporate Disclosure” from the Securities Analysts Association of Japan

10/19/2021 | 09:41pm EST

TOKYO, October 20, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that the company has ranked first in the pharmaceuticals sector for the "2021 Award for Excellence in Corporate Disclosure" granted by the Securities Analysts Association of Japan (SAAJ) to promote the quality and fairness of corporate disclosure.

Astellas was highly evaluated mainly in the following areas:

  • Significant improvement in IR stance, with the top management's proactive information dissemination and engagement in dialogue
  • IR group has sufficient accumulated information, and securities analysts and institutional investors are having a useful dialogue with IR personnel
  • Announcement of a medium-term plan ("Corporate Strategic Plan 2021" *1), a full explanation of subsequent progress with concrete measures for achievement, and a capital allocation policy
  • Stock market needs are incorporated into the disclosure materials of the medium-term plan

Astellas' raison d'être is "to contribute toward improving the health of people around the world through the provision of innovative and reliable pharmaceutical products." With research and development at the heart of the company, Astellas constantly takes on challenges to deliver innovative new drugs and medical solutions by leveraging its core capabilities. In addition, Astellas aims to sustainably enhance its enterprise value by being chosen and trusted by all the stakeholders including customers, shareholders, employees and community.

Upon receiving the award, Kenji Yasukawa, President and CEO, Astellas, stated as follows:
"Our disclosure philosophy is to make our products on the market and the clinical trial results known in a timely and appropriate manner, as well as proactively explain to the stakeholders not only the features of the projects under research and development, but also the potential impact on society when they are launched. In addition, we strive to make the opportunity to provide information flexibly in line with the requests and needs of the stakeholders so that we do not unilaterally disseminate information. As a result of these efforts, we believe that we were able to improve the perception of our advocacy activities and our disclosure philosophy, which led to this recognition."

Astellas will continue to disclose information in a timely, appropriate, and fair manner, as well as proactively engage in dialogue with stakeholders and further improve transparency. Astellas will continue to strive to enhance and improve the quality of its disclosure.

For details on regarding the "Excellence in Corporate Disclosure," please refer to the website of the SAAJ (https://www.saa.or.jp/english/research/disclosure.html).

*1: Astellas Corporate website "Corporate Strategic Plan 2021". Available at:
https://www.astellas.com/en/about/csp2021

Click below for a copy of the full press release

Disclaimer

Astellas Pharma Inc. published this content on 20 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 October 2021 01:40:04 UTC.


ę Publicnow 2021
All news about ASTELLAS PHARMA INC.
08:26aAstellas to Present Research on FLT3 Mutation, Positive Acute Myeloid Leukemia from Dia..
AQ
01:23aJapanese shares end lower on Omicron worries, Fed's hawkish tilt
RE
12/01Japanese shares fall on Omicron, Fed worries
RE
12/01ASTELLAS PHARMA : to Present Research on FLT3 Mutation-Positive Acute Myeloid Leukemia &nd..
PU
11/30ASTELLAS PHARMA : Patient centricity at Astellas—all about action
PU
11/30WE PUBLISHED A STORY : “Patient centricity at Astellas—all about action.&rdquo..
PU
11/26ASTELLAS PHARMA : Annual Report 2021 is now available.
PU
11/25ASTELLAS PHARMA : Pivotal Phase 3 Trial for Pediatric Praziquantel Completes with Positive..
PU
11/19ASTELLAS PHARMA : ' Efforts Against the Spread of the Coronavirus Disease (COVID-19)
PU
11/14ASTELLAS PHARMA : and Pantherna Enter into Technology Evaluation Agreement for Research of..
PU
More news
Financials
Sales 2022 1 327 B 11 729 M 11 729 M
Net income 2022 183 B 1 617 M 1 617 M
Net cash 2022 380 B 3 358 M 3 358 M
P/E ratio 2022 17,8x
Yield 2022 2,82%
Capitalization 3 287 B 29 075 M 29 047 M
EV / Sales 2022 2,19x
EV / Sales 2023 1,92x
Nbr of Employees 15 455
Free-Float 98,9%
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Last Close Price 1 774,00 JPY
Average target price 2 458,33 JPY
Spread / Average Target 38,6%
EPS Revisions
Managers and Directors
Kenji Yasukawa President, CEO & Representative Director
Naoki Okamura CFO, Representative Director & Vice President
Yoshihiko Hatanaka Chairman
Yoshitsugu Shitaka Chief Scientific Officer
Fumiaki Sakurai Head-Business Administration & Compliance
Sector and Competitors
1st jan.Capi. (M$)
ASTELLAS PHARMA INC.11.29%28 790
JOHNSON & JOHNSON0.44%416 161
ROCHE HOLDING AG18.38%343 323
PFIZER, INC.48.55%306 912
NOVO NORDISK A/S66.91%247 444
ELI LILLY AND COMPANY47.55%225 859